Voglibose
You don't need to be Editor-In-Chief to add or edit content to WikiDoc. You can begin to add to or edit text on this WikiDoc page by clicking on the edit button at the top of this page. Next enter or edit the information that you would like to appear here. Once you are done editing, scroll down and click the Save page button at the bottom of the page.
Please Take Over This Page and Apply to be Editor-In-Chief for this topic: There can be one or more than one Editor-In-Chief. You may also apply to be an Associate Editor-In-Chief of one of the subtopics below. Please mail us [1] to indicate your interest in serving either as an Editor-In-Chief of the entire topic or as an Associate Editor-In-Chief for a subtopic. Please be sure to attach your CV and or biographical sketch.
| |
| Voglibose
| |
| Systematic (IUPAC) name | |
| (1S,2S,3R,4S,5S)-5-(1,3-dihydroxypropan-2-ylamino)- 1-(hydroxymethyl)cyclohexane-1,2,3,4-tetrol | |
| Identifiers | |
| CAS number | |
| ATC code | A10 |
| PubChem | |
| Chemical data | |
| Formula | C10H21NO7 |
| Mol. mass | 267.28 g/mol |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
|
WikiDoc Resources for Voglibose | |
|
Articles | |
|---|---|
|
Most recent articles on Voglibose | |
|
Media | |
|
Evidence Based Medicine | |
|
Clinical Trials | |
|
Ongoing Trials on Voglibose at Clinical Trials.gov Clinical Trials on Voglibose at Google
| |
|
Guidelines / Policies / Govt | |
|
US National Guidelines Clearinghouse on Voglibose
| |
|
Books | |
|
News | |
|
Commentary | |
|
Definitions | |
|
Patient Resources / Community | |
|
Patient resources on Voglibose Discussion groups on Voglibose Directions to Hospitals Treating Voglibose Risk calculators and risk factors for Voglibose
| |
|
Healthcare Provider Resources | |
|
Causes & Risk Factors for Voglibose | |
|
Continuing Medical Education (CME) | |
|
International | |
|
| |
|
Businness | |
|
Experimental / Informatics | |
Voglibose (INN and USAN) is an alpha-glucosidase inhibitor used for lowering post-prandial blood glucose levels in people with diabetes mellitus. It is made in India by Ranbaxy Labs and sold under the trade name Volix.
Glenmark is also producing voglibose under brand name vocarb.
Diabetes is chronic metabolic disorder characterised by hyperglycemia which is due to relative or absolute deficiency of insulin or insulin resistance.
PPHG is termed as Post Prandial Hyperglycemia which is primarily due to first phase insulin secretion. Alpha glucosidase inhibitor is one agent which delays the glucose absorption at the intestine level and thereby prevents sudden surge of glucose post meal.
There are three molecules which belong to this class namely, Acarbose, Miglitol and Voglibose. Voglibose is the latest molecule in this class. Voglibose scores over both Acarbose and MIglitol in terms of potency and side effect profile.
There are several trials supporting the use of Voglibose in the management of PPHG. Also, it has been established that it is PPHG not FPG which is marker of cardiovascular disorders associated with diabetes. So, controlling PPHG is imperative and Voglibose is indicated for the management of PPHG.
Sun Pharmaceuticals launched Voglibose 0.2 / 0.3 mg under the brand name VOLIBO.
External links
Oral antidiabetic drugs and Insulin analogs (A10) | |
|---|---|
| Biguanides | Metformin |
| Sulfonylureas | Chlorpropamide, Glibenclamide (Glyburide), Gliclazide, Glimepiride, Glipizide, Gliquidone, Tolazamide, Tolbutamide |
| Alpha-glucosidase inhibitors | Acarbose, Miglitol, Voglibose |
| Thiazolidinediones (TZD) | Pioglitazone, Rivoglitazone†, Rosiglitazone, Troglitazone‡ |
| Meglitinides | Nateglinide, Repaglinide, Mitiglinide |
| Dipeptidyl peptidase-4 (DPP-4) inhibitors | Alogliptin†, Saxagliptin†, Sitagliptin, Vildagliptin, Linagliptin† |
| Glucagon-like peptide-1 analog | Exenatide, Liraglutide†, Albiglutide† |
| Amylin analog | Pramlintide |
| Insulin analogs | fast acting (Insulin lispro, Insulin aspart, Insulin glulisine), long acting (Insulin glargine, Insulin detemir) |
| Dual PPAR agonists | Aleglitazar†, Muraglitazar§, Tesaglitazar§ |
| SGLT2 inhibitor | Dapagliflozin†, Remogliflozin† |
| †Undergoing clinical trials. ‡ Withdrawn from market. §Development halted. | |
Acknowledgement and Attribution Regarding Sources of Content
Some of the initial content on this page may be incorporated in part from copyleft sources in the public domain including wikis such as Wikipedia and AskDrWiki. Drug information for patients came from the The National Library of Medicine. Infectious disease information may have come from the Centers for Disease Control (CDC). Differential Diagnoses are drawn from clinicians as well as an amalgamation of 3 sources: 1.The Disease Database; 2. Kahan, Scott, Smith, Ellen G. In A Page: Signs and Symptoms. Malden, Massachusetts: Blackwell Publishing, 2004:3; 3. Sailer, Christian, Wasner, Susanne. Differential Diagnosis Pocket. Hermosa Beach, CA: Borm Bruckmeir Publishing LLC, 2002:7 .
